Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.41 |
| ▸ | RORC | P51449 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893297 | 0.84 | KDM4E (0.51) | OPRK1BCHEHDAC1HDAC6HDAC8 | |
| SCHEMBL4892318 | 0.78 | HDAC1 (0.38) | OPRK1BCHEHDAC1HDAC6HDAC8 | |
| SCHEMBL14005308 | 0.78 | HDAC1 (0.44) | OPRK1HDAC1HDAC6HDAC8SMN1; SMN2 | |
| SCHEMBL4888123 | 0.76 | KMT2A (0.39) | HDAC1HDAC6SMN1; SMN2KDM4E | |
| SCHEMBL14005311 | 0.74 | CXCR4 (0.51) | OPRK1HDAC1HDAC6SMN1; SMN2 | |
| SCHEMBL14030731 | 0.73 | CXCR4 (0.39) | OPRK1HDAC1HDAC6KDM4E | |
| SCHEMBL4892312 | 0.73 | CXCR4 (0.45) | OPRK1HDAC1HDAC6HDAC8SMN1; SMN2 | |
| SCHEMBL14005295 | 0.70 | HDAC1 (0.46) | OPRK1HDAC1HDAC6HDAC8SMN1; SMN2 | |
| SCHEMBL9640535 | 0.69 | TSHR (0.51) | BCHEHDAC1HDAC8RORCHDAC3 | |
| SCHEMBL4744997 | 0.68 | ACHE (0.51) | OPRK1BCHEHDAC1HDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008112156-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | OPRK1 130/4885BCHE 4575/4885HDAC1 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.